

Lifetime Probability of Developing and Dying from Cancer, 2011-2013

	MALES				FEMALES			
	Developing		Dying		Developing		Dying	
	%	1 in...	%	1 in...	%	1 in...	%	1 in...
All Sites*	40.8	2	22.3	4	37.5	3	18.9	5
Brain & ONS	0.7	144	0.5	194	0.5	184	0.4	246
Breast	0.1	806	<0.1	3,168	12.4	8	2.6	38
Colorectal	4.6	22	1.9	51	4.2	24	1.8	57
Esophagus	0.8	128	0.8	129	0.2	455	0.2	490
Hodgkin lymphoma	0.2	436	<0.1	2,386	0.2	523	<0.1	3,268
Kidney & renal pelvis	2.1	48	0.6	163	1.2	83	0.3	292
Larynx	0.6	175	0.2	503	0.1	806	<0.1	2,063
Leukemia	1.8	57	1.0	97	1.2	81	0.7	140
Liver & intrahepatic bile duct	1.4	74	1.0	103	0.6	176	0.5	200
Lung & bronchus	7.0	14	6.1	16	6.0	17	4.8	21
Melanoma of skin†	3.5	28	0.5	192	2.3	44	0.3	395
Myeloma	0.9	114	0.5	210	0.6	155	0.4	258
Non-Hodgkin lymphoma	2.4	42	0.9	117	1.9	54	0.7	150
Oral cavity & pharynx	1.6	63	0.4	251	0.7	148	0.2	558
Ovary	--	--	--	--	1.3	78	0.9	106
Pancreas	1.6	64	1.4	73	1.5	66	1.3	75
Prostate	12.9	8	2.5	40	--	--	--	--
Stomach	1.1	95	0.5	213	0.7	152	0.3	319
Testis	0.4	259	<0.1	5,167	--	--	--	--
Thyroid	0.6	163	0.1	1,773	1.8	57	0.1	1,451
Urinary bladder‡	3.8	26	0.9	108	1.1	89	0.3	291
Uterine cervix	--	--	--	--	0.6	161	0.2	440
Uterine corpus	--	--	--	--	2.8	36	0.6	169

*All sites excludes basal cell and squamous cell skin cancers and in situ cancers except urinary bladder.

†Statistics are for non-Hispanic whites.

‡Includes invasive and in situ cancer cases.

Source: Software: DevCan: Probability of Developing or Dying of Cancer Software, Version 6.7.4, National Cancer Institute, 2016.